Tarsus Q4 XDEMVY sales $66.4M; full-year $180.1M; net loss narrows to $0.60/share

Tarsus Pharmaceuticals, Inc.

2024-FY EPS reported -$3.07 revenue$182,953,000

Q4 net product sales $66.4M (vs $13.1M YoY); full-year $180.1M (vs $14.7M), with 163,000 bottles dispensed in 2024.
Net loss $23.1M ($0.60/share) in Q4 vs $41.9M ($1.31) in Q4 2023; full-year loss $115.6M ($3.07) vs $135.9M ($4.62).
Cash and marketable securities $291.4M as of Dec 31, 2024; gross-to-net discount ~45% on XDEMVY.
Pipeline: TP-04 for ocular rosacea on track to start Phase 2 in H2 2025; TP-05 for Lyme disease Phase 2 study planned.
Appointed Dr. Elizabeth Yeu as CMO and Dr. Katherine Goodrich to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.